Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated:  8/31/2017
Fox Chase Cancer Center - Philadelphia
1229
mi
from
Philadelphia, PA
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated: 8/31/2017
Fox Chase Cancer Center - Philadelphia
1229
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated:  8/31/2017
M. D. Anderson Cancer Center at University of Texas
572
mi
from
Houston, TX
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated: 8/31/2017
M. D. Anderson Cancer Center at University of Texas
572
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated:  8/31/2017
University of Virginia Cancer Center
1051
mi
from
Charlottesville, VA
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
Status: Enrolling
Updated: 8/31/2017
University of Virginia Cancer Center
1051
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/5/2017
UPMC Cancer Centers
975
mi
from
Pittsburgh, PA
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/5/2017
UPMC Cancer Centers
975
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
676
mi
from
Birmingham, AL
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
676
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
737
mi
from
Mobile, AL
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
737
mi
from
Mobile, AL
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
1142
mi
from
La Jolla, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1142
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
1179
mi
from
Los Angeles, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1179
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
1340
mi
from
San Francisco, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
1328
mi
from
Vallejo, CA
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1328
mi
from
Vallejo, CA
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
1144
mi
from
Orlando, FL
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1144
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
643
mi
from
Indianapolis, IN
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
810
mi
from
Ann Arbor, MI
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
810
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
1393
mi
from
Lebanon, NH
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1393
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
1290
mi
from
New York, NY
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
1290
mi
from
New York, NY
Click here to add this to my saved trials
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated:  9/6/2017
GSK Investigational Site
8658
mi
from
Westmead,
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Status: Enrolling
Updated: 9/6/2017
GSK Investigational Site
8658
mi
from
Westmead,
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Ironwood Cancer and Research Centers
845
mi
from
Chandler, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Ironwood Cancer and Research Centers
845
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Omni Dermatology
846
mi
from
Phoenix, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Omni Dermatology
846
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Alliance Dermatology & MOHS Center, PC
844
mi
from
Phoenix, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Alliance Dermatology & MOHS Center, PC
844
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
University of Arizona Cancer Center
833
mi
from
Tucson, AZ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Arizona Cancer Center
833
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Highlands Oncology Group, P.A.
234
mi
from
Fayetteville, AR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Highlands Oncology Group, P.A.
234
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Burke Pharmaceutical Research
348
mi
from
Hot Springs, AR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Burke Pharmaceutical Research
348
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
City of Hope
1152
mi
from
Duarte, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
City of Hope
1152
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
The Angeles Clinic & Research Institute
1168
mi
from
Los Angeles, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
The Angeles Clinic & Research Institute
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Ventura County Hematology Oncology Specialists
1215
mi
from
Oxnard, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Ventura County Hematology Oncology Specialists
1215
mi
from
Oxnard, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Sutter Cancer Center
1282
mi
from
Sacramento, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Sutter Cancer Center
1282
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Northern California Melanoma Center, St. Mary's Medical Center
1340
mi
from
San Francisco, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Northern California Melanoma Center, St. Mary's Medical Center
1340
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Advanced Dermatology and Skin Cancer Specialists
1122
mi
from
Temecula, CA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Advanced Dermatology and Skin Cancer Specialists
1122
mi
from
Temecula, CA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Anschutz Cancer Pavilion
402
mi
from
Aurora, CO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Anschutz Cancer Pavilion
402
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Skin Care research Inc
mi
from
Boca Raton, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Skin Care research Inc
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Cancer Specialists of North Florida
mi
from
Jacksonville, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Cancer Specialists of North Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Mount Sinai Medical Center
1322
mi
from
Miami Beach, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Mount Sinai Medical Center
1322
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Lake Research LLC
1309
mi
from
Miami Lakes, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Lake Research LLC
1309
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
M.D. Anderson Cancer Center at Orlando
1142
mi
from
Orlando, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
M.D. Anderson Cancer Center at Orlando
1142
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Ameriderm Research
1125
mi
from
Ormond Beach, FL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Ameriderm Research
1125
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Oncology Specialists, SC (OSSC)
607
mi
from
Niles, IL
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Oncology Specialists, SC (OSSC)
607
mi
from
Niles, IL
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Investigative Clinical Research of Indiana
638
mi
from
Indianapolis, IN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Investigative Clinical Research of Indiana
638
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
University of Iowa Hospitals and Clinics
429
mi
from
Iowa City, IA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Iowa Hospitals and Clinics
429
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Central Kentucky Research Associates, Inc.
731
mi
from
Lexington, KY
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Central Kentucky Research Associates, Inc.
731
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
University of Louisville
656
mi
from
Louisville, KY
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Louisville
656
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Clinical Research Facility
583
mi
from
Lake Charles, LA
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Clinical Research Facility
583
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Harry and Jeanette Weinberg Cancer Institute at Franklin Square
1154
mi
from
Baltimore, MD
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Harry and Jeanette Weinberg Cancer Institute at Franklin Square
1154
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Providence Cancer Institute
835
mi
from
Southfield, MI
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Providence Cancer Institute
835
mi
from
Southfield, MI
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
University of Minnesota Masonic Cancer Institute
mi
from
Minneapolis, MN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
University of Minnesota Masonic Cancer Institute
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Mayo Clinic Cancer Center, Mayo Clinic Rochester
515
mi
from
Rochester, MN
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Mayo Clinic Cancer Center, Mayo Clinic Rochester
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
The Center for Pharmaceutical Research, P.C.
193
mi
from
Kansas City, MO
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
The Center for Pharmaceutical Research, P.C.
193
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
1393
mi
from
Lebanon, NH
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
1393
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
E. Carolina University; Brody School of Medicine
1140
mi
from
Greenville, NC
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
E. Carolina University; Brody School of Medicine
1140
mi
from
Greenville, NC
Click here to add this to my saved trials
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated:  9/6/2017
Wake Forest University School of Medicine, Comprehensive Cancer Center
976
mi
from
Winston-Salem, NC
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Status: Enrolling
Updated: 9/6/2017
Wake Forest University School of Medicine, Comprehensive Cancer Center
976
mi
from
Winston-Salem, NC
Click here to add this to my saved trials